Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01872130 · ClinicalTrials.gov registry record
Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins
A clinical trial of Squamous Cell Carcinoma and Basal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 45
- Enrollment target
- 4
- Study locations
NCT01872130: Completed study of Squamous Cell Carcinoma and Basal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01872130 is a study of Squamous Cell Carcinoma and Basal Cell Carcinoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 45 participants, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (56% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01872130, a study of Squamous Cell Carcinoma and Basal Cell Carcinoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate a new instrument that shines light and takes digital pictures of skin. The goal is to develop a technique that may enable fast and accurate assessment of surgical margins in the excision of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). The investigators will evaluate the pictures obtained by the confocal microscope to determine whether this technique may be useful in the future for helping Mohs surgeons remove cancers. In the future, patients may benefit with shorter surgery and improved care.
Primary Outcome
For the primary study objective, the Mohs surgeon will perform a qualitative assessment of the confocal mosaic. This will be a dichotomous assessment of whether the mosaic is of sufficient quality (contrast and resolution) to identify individual features. The specific features for BCC or SCC margins are tumor nests with nuclear atypia and increased nuclear density (relative to the density seen in normal basal cells).
Conditions Studied
Study Locations (4)
New York
- Memorial Sloan Kettering West Harrison - Harrison
- Memorial Sloan Kettering Cancer Center Hauppauge - Hauppauge
- Memorial Sloan Kettering Cancer Center - New York
New Jersey
- Memorial Sloan Kettering at Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2013-05 |
| Est. Completion | 2020-04-28 |
What the finished NCT01872130 record still lists
NCT01872130 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (56% lower).
The record links to 2 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT01872130 reports a single indexed study location in New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01872130 about?
NCT01872130 is a clinical study titled "Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins". The purpose of this study is to evaluate a new instrument that shines light and takes digital pictures of skin. The goal is to develop a technique that may enable fast and accurate assessment of surgical margins in the excision of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). The inve...
What is the current status of trial NCT01872130?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2013-05. Estimated completion is 2020-04-28.
What conditions does trial NCT01872130 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Basal Cell Carcinoma.
Who is sponsoring clinical trial NCT01872130?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01872130 being conducted?
This trial has 4 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01872130's enrollment target sits among peer trials
45 23rd of 47 higher than 24 of 47 other Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
RECRUITING · Phase 2
-
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
RECRUITING · NA
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
RECRUITING · Phase 1
-
Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain
RECRUITING · NA
-
Toripalimab With Chemotherapy for Sinus Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia